Physicians' Academy for Cardiovascular Education

Diabetes

Diabetes is now considered an important risk factor for cardiovascular disease, and a complex interplay of pathogenic factors complicates management of both diseases.

Triglycerides most commonly a marker of ectopic fat accumulation

5' education - July 20, 2022 - Prof. Naveed Sattar, MD, PhD

Discussion - Preventing CKD in patients with diabetes - Exploring the current and future role of GLP-1RA

10' education - July 6, 2022 - Prof. Johannes Mann, MD, prof. Filip Knop, MD, PhD, and prof. Katherine Tuttle, MD

Clinical dialogue: Lowering ASCVD risk in a patient with T2DM and obesity

15' education - July 5, 2022 - Prof. Nikolaus Marx, MD and Adie Viljoen, MD

Clinical dialogue: CV risk in diabetes

15' education - June 22, 2022 - Prof. Nikolaus Marx, MD and Michael Lehrke, MD

Which patients with CKD and diabetes will benefit from management with GLP-1RA?

10' education - June 13, 2022 - Prof. Katherine Tuttle, MD

Cardiorenal effects of nonsteroidal MRAs in patients with CKD and T2DM

10' education - June 7, 2022 - Eugene E. Wright, Jr., MD, Jolanta Małyszko, MD, PhD and María José Soler, MD, PhD

New insights and guidelines for the management of CKD and diabetes

10' education - May 31, 2022 - Prof. Johannes Mann, MD

Wide distribution of CVD-free life-years gained with GLP-1RA

5' education - Mar. 21, 2022 - Jan Westerink, MD, PhD

Role of a non-steroidal MRA in the treatment spectrum of patients with T2DM and CKD

10' education - Feb. 8, 2022 - Prof. Peter Rossing, MD, prof. Gerasimos Filippatos, MD and prof. Matthew Weir, MD

Rethinking responsibilities in the prevention and management of cardiometabolic disease

10' education - Dec. 7, 2021 - Prof. Stephan Jacob, MD

What is the effect of low-dose aspirin on dementia risk in T2DM?

3' education - Nov. 16, 2021 - Prof. Jane Armitage

Symposium on the role of SGLT2i in tackling cardiorenal risk in diabetes

15' education - Oct. 28, 2021 - Prof. Melanie Davies, MD and prof. Nikolaus Marx, MD - Online CME

Dialogue on how to overcome clinical inertia with regard to SGLT2i

10' education - Oct. 28, 2021 - Prof. Melanie Davies, MD and prof. Nikolaus Marx, MD - Online CME

SGLT2i: Overview of recent trials and guideline recommendations

10' education - Oct. 28, 2021 - Prof. Nikolaus Marx, MD - Online CME

Introduction on tackling cardiorenal risk in diabetes

10' education - Oct. 28, 2021 - Prof. Melanie Davies, MD - Online CME

CV outcomes reduced by nonsteroidal MRA in patients with diabetes and CKD

3' education - Aug. 28, 2021 - Kevin Damman, MD, PhD

Where do GLP-1RA fit in in current and future management of CKD?

10' education - July 26, 2021 - Frederik Persson, MD - Online CME

Treatment goals for patients with T2DM and CKD

10' education - July 13, 2021 - Prof. Peter Rossing, MD - Online CME

How can GLP-1RA benefit a patient with diabetes and CKD?

10' education - July 1, 2021 - Daniël van Raalte, MD, PhD - Online CME

Practical challenges with SGLT2i therapy in patients with T2DM and CKD

10' education - June 29, 2021 - Alice Cheng, MD - Online CME

Prevention strategies in patients with CKD and T2DM

10' education - June 24, 2021 - Ofri Mosenzon, MD - Online CME

Clinical inertia in CKD - What is the rationale for SGLT2i?

10' education - June 21, 2021 - Janaka Karalliedde, MD, PhD - Online CME

Reduction in albuminuria predicts future benefits on CV and renal outcomes in T2DM

10' education - Feb. 22, 2021 - Frederik Persson, MD
5 Things a cardiologist needs to know about GLP-1 RA

GLP-1RAs: What are the future directions in development?

10' education - Jan. 6, 2021 - Prof. John Deanfield, MD - Online CME
5 Things a cardiologist needs to know about GLP-1 RA

What is the clinical evidence for the benefits of GLP-1RAs?

10' education - Dec. 10, 2020 - Prof. Subodh Verma, MD - Online CME

Newest ESC guidelines on diabetes and CVD

10' education - Nov. 24, 2020 - Prof. Francesco Cosentino, MD - Online CME

Novel findings with dual SGLT1 and SGLT2 inhibitor in diabetes patients

5' education - Nov. 23, 2020 - Prof. Deepak Bhatt, MD
5 Things a cardiologist needs to know about GLP-1RA

Which patients to consider for GLP-1RA?

10' education - Nov. 18, 2020 - Prof. Stephan Jacob, MD - Online CME

The role of GLP-1 receptor agonists in CVD prevention

10' education - Nov. 6, 2020 - Prof. Kamlesh Khunti, MD - Online CME

The role for primary care in reducing CV risk in diabetes

10' education - Oct. 20, 2020 - Prof. Richard Hobbs, MD - Online CME

SGLT2i attenuates longitudinal rises in CV biomarkers in T2DM patients

Literature - July 25, 2022 - Vaduganathan M, et al. - J Am Coll Cardiol. 2022

The CANVAS biomarker substudy showed that canagliflozin delays the expected increase in CV biomarkers in T2DM patients. It also reduces the risk of HF and renal disease events irrespective of biomarker levels at baseline.

Triglycerides most commonly a marker of ectopic fat accumulation

5' education - July 20, 2022 - Prof. Naveed Sattar, MD, PhD
Prof. Sattar shares his thoughts on why high triglycerides reflect ectopic fat and how this relationship may help to motivate patients to sustain weight improvements and lower CV and diabetes risks.

Prof. Sattar shares his thoughts on why high triglycerides reflect ectopic fat and how this relationship may help to motivate patients to sustain weight improvements and lower CV and diabetes risks.

E-learning Preventing CKD in patients with diabetes - Exploring the current and future role of GLP-1RA

Accredited e-Learning

Online-CME - This course consists of 3 parts.
This course consists of 3 parts.

Three speakers present the KDIGO guidelines, evidence of studies with GLP-1RAs and kidney outcomes and tell us what we can expect in the near future with regard to GLP-1RAs in nephrology.

E-learning Clinical dialogues on CV risk in diabetes

Accredited e-Learning

Online-CME - This course consists of 2 parts.
This course consists of 2 parts.

How should you treat a patient with T2DM and multiple CV risk factors? In this series, two duos both present such a case and discuss the optimal treatment strategy.

Discussion - Preventing CKD in patients with diabetes - Exploring the current and future role of GLP-1RA

10' education - July 6, 2022 - Prof. Johannes Mann, MD, prof. Filip Knop, MD, PhD, and prof. Katherine Tuttle, MD
Watch a discussion by three experts on the role of GLP-1RA in preventing CKD in patients with diabetes.

Watch a discussion by three experts on the role of GLP-1RA in preventing CKD in patients with diabetes.

Clinical dialogue: Lowering ASCVD risk in a patient with T2DM and obesity

15' education - July 5, 2022 - Prof. Nikolaus Marx, MD and Adie Viljoen, MD

"Multifactorial risk factor approach is important for patients with T2DM", says Adie Viljoen. He presents a case of a patient with T2DM and multiple CV risk factors. Together with prof. Marx, he discusses the treatment plan for this patient.

Clinical dialogue: CV risk in diabetes

15' education - June 22, 2022 - Prof. Nikolaus Marx, MD and Michael Lehrke, MD
Prof. Marx and Prof. Lehrke discuss a case of a 64-year old patient with T2DM and acute MI. What is the best way to address the CV risk in this patient?

Prof. Marx and Prof. Lehrke discuss a case of a 64-year old patient with T2DM and acute MI. What are the treatment options in this patient?

Updates to the Standards of Medical Care in Diabetes 2022 by ADA

News - June 21, 2022

The American Diabetes Association (ADA) has made important updates to the Standard of Medical Care in Diabetes 2022. Updates include new data on finerenone in T2DM and CKD, SGLT2i in T2DM and calculating eGFR.

Which patients with CKD and diabetes will benefit from management with GLP-1RA?

10' education - June 13, 2022 - Prof. Katherine Tuttle, MD
In this video, Prof. Tuttle discusses GLP-1RAs for CVD risk reduction and preservation of kidney function in CKD. Moreover, she talks about multidisciplinary team care for patients with T2DM and CKD.

In this video, Prof. Tuttle discusses GLP-1RAs for CVD risk reduction and preservation of kidney function in CKD. Moreover, she talks about multidisciplinary team care for patients with T2DM and CKD.

Pooled analysis shows no new safety concerns of SGLT2i in T2DM patients with CKD

Literature - June 8, 2022 - Tuttle KR, et al. - Diabetes Care. 2022

By pooling data from 20 RCTs, researchers analyzed the adverse event rate with empagliflozin versus placebo in 2367 T2DM patients with moderate to severe CKD.

Cardiorenal effects of nonsteroidal MRAs in patients with CKD and T2DM

10' education - June 7, 2022 - Eugene E. Wright, Jr., MD, Jolanta Małyszko, MD, PhD and María José Soler, MD, PhD
In this video, three physicians talk about the results of the FIDELIO-DKD and FIGARO-DKD studies and the FIDELLITY analysis and discuss the clinical implications of initiating nonsteroidal MRAs in patients with CKD and T2DM.

In this video, three physicians talk about the results of the FIDELIO-DKD and FIGARO-DKD studies and the FIDELLITY analysis and discuss the clinical implications of initiating nonsteroidal MRAs in patients with CKD and T2DM.

Cardiologists account for small proportion of all use of SGLT2is and GLP-1RAs

Literature - May 31, 2022 - Adhikari R, et al. - J Am Heart Assoc. 2022

Although American cardiologists are increasingly prescribing SGLT2is and GLP‐1RAs since 2015, they accounted for <2% of all use in 2020. This could contribute to the known undertreatment of T2DM patients with high CVD risk.